Sharechat Logo

SeaDragon's funding transaction unfair but positives outweigh negatives, say independent advisers

Friday 20th July 2018

Text too small?

SeaDragon's proposed funding transaction is not fair to non-associated shareholders but the positives outweigh the negatives given the position in the company is in, according to independent advisers Campbell MacPherson. 

"SeaDragon is currently cash constrained and requires an immediate injection of capital to fund operating losses and execute its business plan. In the event that funding is not secured it is highly likely that the directors will have no option but to place the company into receivership or liquidation," according to the advisers' report.

The fish oil manufacturer has forecast a net loss of between $3.6 million and $4.6 million in the year ending March 31, 2019, and said its ability to deliver on its forecast depends on securing long-term funding for the company.

SeaDragon hammered out a deal under which Australian investment firm BioScience Managers and Pescado Holdings, which is associated with Christchurch's rich-lister Stewart family, each agreed to advance up to $3 million via a new convertible loan note facility. An existing convertible loan note facility and existing option to purchase $3 million of ordinary shares in SeaDragon with Comvita will be amended. 

The deal requires shareholder approval at the Aug. 8 annual general meeting in Auckland. 

According to the advisers, the main negative aspect is that the assessed value per convertible loan note exceeds the consideration offered by Pescado, Bioscience and Comvita for each note. Campbell MacPherson has assessed the value of the convertible loan notes to be in the range of $1.03 to $1.23 per note. Each note is being issued for a consideration of $1.

"In our view, this is the key criteria in assessing that the proposed transactions are 'not fair' to the non-associated shareholders," it said.

It also said the potential allotment of shares to Pescado, Bioscience and Comvita as a result of the conversion of the loans and/or the exercise of the Comvita option would be dilutive to the non-associated shareholders.

On the positive side, it said the deal will collectively provide essential funding for the company. It noted the SeaDragon board does not expect the full $6 million to be drawn down and therefore "a $6 million facility does provide the company with a degree of certainty in the event that additional funding is required in the short to medium-term." 

it also said that the interest rate structure is favourable to SeaDragon.

SeaDragon shares last traded at $0.004 or four-tenths of a cent.

(BusinessDesk)

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MARKET CLOSE: NZ shares rise as optimism over US-China trade deal lingers; Fletcher gains
NZD under pressure against Aussie as investors cheered by easing of trade jitters
PFI properties’ valuation rises 5.5% to $1.32 billion
Broader definition of workplace harm in new govt health & safety strategy
MBIE officials grilled on terms of Westland Milk loan
Trade Me suitor Hellman & Friedman drops out
Hydrogen not a short-term option for Huntly - Genesis
Kiwibank says customers have a dwindling need of physical branches
Buying off the plans driving down KiwiBuild cost to govt: HYEFU
Fiscal policy to slow growth over next five years, despite surpluses

IRG See IRG research reports